<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 22 Mar 2025 18:14:02 +0000</lastbuilddate>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Answer: an uncommon electrocardiogram pattern in a case of acute chest pain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40118096/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Acute Cardiovasc Care. 2025 Mar 22:zuaf020. doi: 10.1093/ehjacc/zuaf020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40118096/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40118096</a> | DOI:<a href=https://doi.org/10.1093/ehjacc/zuaf020>10.1093/ehjacc/zuaf020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40118096</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Gulbadin Mufti</dc:creator>
<dc:creator>Shahid H Shali</dc:creator>
<dc:creator>A Shaheer Ahmed</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal. Acute cardiovascular care</dc:source>
<dc:title>Answer: an uncommon electrocardiogram pattern in a case of acute chest pain</dc:title>
<dc:identifier>pmid:40118096</dc:identifier>
<dc:identifier>doi:10.1093/ehjacc/zuaf020</dc:identifier>
</item>
<item>
<title>Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40118046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>Understanding how proteins in different mammalian tissues are regulated is central to biology. Protein abundance, turnover, and post-translational modifications such as phosphorylation are key factors that determine tissue-specific proteome properties. However, these properties are challenging to study across tissues and remain poorly understood. Here, we present Turnover-PPT, a comprehensive resource mapping the abundance and lifetime of 11,000 proteins and 40,000 phosphosites in eight mouse...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 14:S0092-8674(25)00209-0. doi: 10.1016/j.cell.2025.02.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Understanding how proteins in different mammalian tissues are regulated is central to biology. Protein abundance, turnover, and post-translational modifications such as phosphorylation are key factors that determine tissue-specific proteome properties. However, these properties are challenging to study across tissues and remain poorly understood. Here, we present Turnover-PPT, a comprehensive resource mapping the abundance and lifetime of 11,000 proteins and 40,000 phosphosites in eight mouse tissues and various brain regions using advanced proteomics and stable isotope labeling. We reveal tissue-specific short- and long-lived proteins, strong correlations between interacting protein lifetimes, and distinct impacts of phosphorylation on protein turnover. Notably, we discover a remarkable pattern of turnover changes for peroxisome proteins in specific tissues and that phosphorylation regulates the stability of neurodegeneration-related proteins, such as Tau and α-synuclein. Thus, Turnover-PPT provides fundamental insights into protein stability, tissue dynamic proteotypes, and functional protein phosphorylation and is accessible via an interactive web-based portal at https://yslproteomics.shinyapps.io/tissuePPT.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40118046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40118046</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.021>10.1016/j.cell.2025.02.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40118046</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Wenxue Li</dc:creator>
<dc:creator>Abhijit Dasgupta</dc:creator>
<dc:creator>Ka Yang</dc:creator>
<dc:creator>Shisheng Wang</dc:creator>
<dc:creator>Nisha Hemandhar-Kumar</dc:creator>
<dc:creator>Surendhar R Chepyala</dc:creator>
<dc:creator>Jay M Yarbro</dc:creator>
<dc:creator>Zhenyi Hu</dc:creator>
<dc:creator>Barbora Salovska</dc:creator>
<dc:creator>Eugenio F Fornasiero</dc:creator>
<dc:creator>Junmin Peng</dc:creator>
<dc:creator>Yansheng Liu</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions</dc:title>
<dc:identifier>pmid:40118046</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.021</dc:identifier>
</item>
<item>
<title>SnapShot: Human sperm-egg interface proteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40118033/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>Human fertilization is a complex, highly regulated process that involves intricate molecular interactions between sperm and egg. Ultimately, this process culminates in the fusion of the gamete membranes to form a zygote. Gene disruption studies in mice have identified several critical fertilization factors. This SnapShot highlights the structure function of key proteins at the sperm-egg interface, providing insights into the mechanism of fertilization. To view this SnapShot, open or download the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20;188(6):1746-1746.e1. doi: 10.1016/j.cell.2025.01.001.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human fertilization is a complex, highly regulated process that involves intricate molecular interactions between sperm and egg. Ultimately, this process culminates in the fusion of the gamete membranes to form a zygote. Gene disruption studies in mice have identified several critical fertilization factors. This SnapShot highlights the structure function of key proteins at the sperm-egg interface, providing insights into the mechanism of fertilization. To view this SnapShot, open or download the PDF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40118033/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40118033</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.001>10.1016/j.cell.2025.01.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40118033</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Emily Forster</dc:creator>
<dc:creator>Xinyin Wang</dc:creator>
<dc:creator>Abenan Thayaparan</dc:creator>
<dc:creator>Jeffrey E Lee</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SnapShot: Human sperm-egg interface proteins</dc:title>
<dc:identifier>pmid:40118033</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.001</dc:identifier>
</item>
<item>
<title>Exploring the plant microbiome: A pathway to climate-smart crops</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40118032/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>The advent of semi-dwarf crop varieties and fertilizers during the Green Revolution boosted yields and food security. However, unintended consequences such as environmental pollution and greenhouse gas emissions underscore the need for strategies to mitigate these impacts. Manipulating rhizosphere microbiomes, an aspect overlooked during crop domestication, offers a pathway for sustainable agriculture. We propose that modulating plant microbiomes can help establish "climate-smart crops" that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20;188(6):1469-1485. doi: 10.1016/j.cell.2025.01.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The advent of semi-dwarf crop varieties and fertilizers during the Green Revolution boosted yields and food security. However, unintended consequences such as environmental pollution and greenhouse gas emissions underscore the need for strategies to mitigate these impacts. Manipulating rhizosphere microbiomes, an aspect overlooked during crop domestication, offers a pathway for sustainable agriculture. We propose that modulating plant microbiomes can help establish "climate-smart crops" that improve yield and reduce negative impacts on the environment. Our proposed framework integrates plant genotype, root exudates, and microbes to optimize nutrient cycling, improve stress resilience, and expedite carbon sequestration. Integrating unselected ecological traits into crop breeding can promote agricultural sustainability, illuminating the nexus between plant genetics and ecosystem functioning.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40118032/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40118032</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.035>10.1016/j.cell.2025.01.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40118032</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>An-Hui Ge</dc:creator>
<dc:creator>Ertao Wang</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Exploring the plant microbiome: A pathway to climate-smart crops</dc:title>
<dc:identifier>pmid:40118032</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.035</dc:identifier>
</item>
<item>
<title>Global surveillance and countermeasures for ACE2-using MERS-related coronaviruses with spillover risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40118031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>Three studies published in this issue of Cell reveal that multiple MERS-related coronaviruses (MERSr-CoVs) utilize ACE2, rather than the canonical Merbecovirus receptor DPP4, for cell entry. These ACE2-dependent MERSr-CoVs pose a risk of zoonotic transmission to humans with high transmissibility potential like SARS-CoV-2, thus calling for global surveillance and countermeasures.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20;188(6):1465-1468. doi: 10.1016/j.cell.2025.02.004.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Three studies published in this issue of Cell reveal that multiple MERS-related coronaviruses (MERSr-CoVs) utilize ACE2, rather than the canonical Merbecovirus receptor DPP4, for cell entry. These ACE2-dependent MERSr-CoVs pose a risk of zoonotic transmission to humans with high transmissibility potential like SARS-CoV-2, thus calling for global surveillance and countermeasures.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40118031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40118031</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.004>10.1016/j.cell.2025.02.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40118031</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shibo Jiang</dc:creator>
<dc:creator>Fan Wu</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Global surveillance and countermeasures for ACE2-using MERS-related coronaviruses with spillover risk</dc:title>
<dc:identifier>pmid:40118031</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.004</dc:identifier>
</item>
<item>
<title>Small-molecule hypoxia therapy in mitochondrial disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40118030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>In this issue of Cell, Blume et al. provide compelling rationale for pursuing pharmacologic optimization of a small-molecule "HypoxyStat," which left-shifts the oxyhemoglobin dissociation curve in red blood cells in an attempt to induce an effective and sustained reduction of chronic tissue hyperoxia in primary mitochondrial disease (PMD) and was well-tolerated and effective for both pre-symptomatic and advanced disease treatment to extend survival and improve neurologic outcomes in a mouse...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20;188(6):1462-1465. doi: 10.1016/j.cell.2025.02.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In this issue of Cell, Blume et al. provide compelling rationale for pursuing pharmacologic optimization of a small-molecule "HypoxyStat," which left-shifts the oxyhemoglobin dissociation curve in red blood cells in an attempt to induce an effective and sustained reduction of chronic tissue hyperoxia in primary mitochondrial disease (PMD) and was well-tolerated and effective for both pre-symptomatic and advanced disease treatment to extend survival and improve neurologic outcomes in a mouse model of Leigh syndrome spectrum.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40118030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40118030</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.019>10.1016/j.cell.2025.02.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40118030</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Marni J Falk</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Small-molecule hypoxia therapy in mitochondrial disease</dc:title>
<dc:identifier>pmid:40118030</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.019</dc:identifier>
</item>
<item>
<title>Transcending life and death: The ultimate cargo of aged neutrophils</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40118029/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>Neutrophils secrete a variety of mediators throughout their lifespan but are mostly associated with pro-inflammatory functions. In this issue of Cell, Hsu et al. describe a new class of extracellular vesicles produced solely by aged neutrophils that elicit anti-inflammatory effects that extend beyond neutrophil lifespan.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20;188(6):1460-1462. doi: 10.1016/j.cell.2025.02.020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Neutrophils secrete a variety of mediators throughout their lifespan but are mostly associated with pro-inflammatory functions. In this issue of Cell, Hsu et al. describe a new class of extracellular vesicles produced solely by aged neutrophils that elicit anti-inflammatory effects that extend beyond neutrophil lifespan.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40118029/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40118029</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.020>10.1016/j.cell.2025.02.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40118029</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lai Guan Ng</dc:creator>
<dc:creator>Immanuel Kwok</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Transcending life and death: The ultimate cargo of aged neutrophils</dc:title>
<dc:identifier>pmid:40118029</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.020</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40117191/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 25;151(8):568-573. doi: 10.1161/CIRCULATIONAHA.125.073856. Epub 2025 Feb 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40117191/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40117191</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073856>10.1161/CIRCULATIONAHA.125.073856</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40117191</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:40117191</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073856</dc:identifier>
</item>
<item>
<title>2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>The level of evidence (LOE) grading system for European Society of Cardiology (ESC) Clinical Practice Guidelines (CPG) classifies the quality of the evidence supporting a recommendation. However, the current taxonomy does not fully consider the optimal study design necessary to establish evidence for different types of recommendations in ESC guidelines. Therefore, two separate task forces of clinical and methodological experts were appointed by the CPG Committee, with the first tasked with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 21:ehaf016. doi: 10.1093/eurheartj/ehaf016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The level of evidence (LOE) grading system for European Society of Cardiology (ESC) Clinical Practice Guidelines (CPG) classifies the quality of the evidence supporting a recommendation. However, the current taxonomy does not fully consider the optimal study design necessary to establish evidence for different types of recommendations in ESC guidelines. Therefore, two separate task forces of clinical and methodological experts were appointed by the CPG Committee, with the first tasked with updating the LOE grading system for therapy and prevention and the second responsible for developing a LOE grading system for diagnosis and prediction. This report from the second of these Task Forces develops a new system for diagnostic tests and prediction models which maintains the three-level grading structure to classify the quality of the evidence but introduces new definitions specific for diagnosis and prediction. For diagnostic tests, LOE A represents conclusive evidence of adequate diagnostic ability from at least two high-quality studies. Level of evidence B represents suggestive evidence from one high-quality or at least two moderate-quality studies. Level of evidence C represents preliminary evidence not classified as A or B, including evidence from less than two moderate-quality studies, or from expert consensus. For prediction models, LOE A represents conclusive evidence of adequate predictive ability from at least one high-quality derivation and two or more external validation studies of at least moderate quality. Level of evidence B represents suggestive evidence in one or more derivation studies and one or more external validation studies of at least moderate quality. Level of evidence C represents preliminary evidence not classified as A or B, including evidence from a derivation study of at least moderate quality, but with low quality or no external validation, or a derivation study of low quality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116738</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf016>10.1093/eurheartj/ehaf016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116738</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Emanuele Di Angelantonio</dc:creator>
<dc:creator>Lisa Pennells</dc:creator>
<dc:creator>Magdy Abdelhamid</dc:creator>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Riccardo Asteggiano</dc:creator>
<dc:creator>Jelena Čelutkienė</dc:creator>
<dc:creator>Diederick E Grobbee</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Peter Jüni</dc:creator>
<dc:creator>John William McEvoy</dc:creator>
<dc:creator>Amina Rakisheva</dc:creator>
<dc:creator>Xavier Rossello</dc:creator>
<dc:creator>Frank L J Visseren</dc:creator>
<dc:creator>Colin Baigent</dc:creator>
<dc:creator>Eva B Prescott</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models</dc:title>
<dc:identifier>pmid:40116738</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf016</dc:identifier>
</item>
<item>
<title>2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>The level of evidence (LOE) grading system for ESC Clinical Practice Guidelines classifies the quality of the evidence supporting a recommendation. However, the current taxonomy does not fully consider the optimal study design necessary to establish evidence for such recommendations. Therefore, two separate taskforces of clinical and methodological experts were appointed by the Clinical Practice Guidelines Committee, with the first tasked with updating the LOE grading system for therapy and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 21:ehaf009. doi: 10.1093/eurheartj/ehaf009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The level of evidence (LOE) grading system for ESC Clinical Practice Guidelines classifies the quality of the evidence supporting a recommendation. However, the current taxonomy does not fully consider the optimal study design necessary to establish evidence for such recommendations. Therefore, two separate taskforces of clinical and methodological experts were appointed by the Clinical Practice Guidelines Committee, with the first tasked with updating the LOE grading system for therapy and prevention, and the second responsible for developing a LOE grading system for diagnosis and prediction. The updated system for therapy and prevention presented here maintains the three-level grading structure but uses revised definitions. Level of evidence A represents conclusive evidence usually from ≥2 adequately powered randomized controlled trials (RCTs) free from major bias, with substantial evidence against the play of chance when combined in a meta-analysis (e.g. P &lt; .005 for superiority). Additional criteria are specified to define substantial evidence against the play of chance in case of non-inferiority, equivalence, and harm. Level of evidence B is now subdivided into B1 and B2. Level of evidence B1 represents suggestive evidence usually from ≥1 adequately powered RCT free from major bias, or a meta-analysis of such RCTs, with some evidence against the play of chance (e.g. P &lt; .05 for superiority). Level of evidence B2 represents limited evidence from ≥2 adequately powered non-randomized studies with careful control of major sources of bias or from a meta-analysis of small, underpowered RCTs. Level of evidence C represents preliminary evidence from either non-randomized studies without careful control of major sources of bias, a single small, underpowered RCT, or expert consensus.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116721</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf009>10.1093/eurheartj/ehaf009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116721</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Peter Jüni</dc:creator>
<dc:creator>Sotiris Antoniou</dc:creator>
<dc:creator>Elena Arbelo</dc:creator>
<dc:creator>Sergio Buccheri</dc:creator>
<dc:creator>Maja Cikes</dc:creator>
<dc:creator>Bruno R da Costa</dc:creator>
<dc:creator>Laurent Fauchier</dc:creator>
<dc:creator>Chris P Gale</dc:creator>
<dc:creator>Sigrun Halvorsen</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:creator>Konstantinos C Koskinas</dc:creator>
<dc:creator>Dipak Kotecha</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Basil S Lewis</dc:creator>
<dc:creator>Maja-Lisa Løchen</dc:creator>
<dc:creator>Jens Cosedis Nielsen</dc:creator>
<dc:creator>Xavier Rosselló</dc:creator>
<dc:creator>Ilonca Vaartjes</dc:creator>
<dc:creator>Eva B Prescott</dc:creator>
<dc:creator>Colin Baigent</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention</dc:title>
<dc:identifier>pmid:40116721</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf009</dc:identifier>
</item>
<item>
<title>Appraisal of the 2024 revision of the level of evidence grading system in European Society of Cardiology Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116710/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 21:ehaf102. doi: 10.1093/eurheartj/ehaf102. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116710/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116710</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf102>10.1093/eurheartj/ehaf102</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116710</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Appraisal of the 2024 revision of the level of evidence grading system in European Society of Cardiology Guidelines</dc:title>
<dc:identifier>pmid:40116710</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf102</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Cristina Basso</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 21:ehaf104. doi: 10.1093/eurheartj/ehaf104. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116225</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf104>10.1093/eurheartj/ehaf104</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116225</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Cristina Basso</dc:title>
<dc:identifier>pmid:40116225</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf104</dc:identifier>
</item>
<item>
<title>Reviving the Swan: Presenting the Chicago Hemodynamic Forum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Heart Fail. 2025 Mar 21:e012725. doi: 10.1161/CIRCHEARTFAILURE.124.012725. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116016</a> | DOI:<a href=https://doi.org/10.1161/CIRCHEARTFAILURE.124.012725>10.1161/CIRCHEARTFAILURE.124.012725</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116016</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mark N Belkin</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>Marat Fudim</dc:creator>
<dc:creator>Ryan J Tedford</dc:creator>
<dc:creator>Jonathan Grinstein</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Heart failure</dc:source>
<dc:title>Reviving the Swan: Presenting the Chicago Hemodynamic Forum</dc:title>
<dc:identifier>pmid:40116016</dc:identifier>
<dc:identifier>doi:10.1161/CIRCHEARTFAILURE.124.012725</dc:identifier>
</item>
<item>
<title>3D Echocardiographic and CMR Imaging for the Assessment of Right Ventricular Function and Tricuspid Regurgitation Severity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: 3DE provides an accurate assessment of TR severity comparable to CMR. The proposed 5-class grading scheme for TR severity using CMR demonstrates high accuracy and external validity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017638. doi: 10.1161/CIRCIMAGING.124.017638. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tricuspid regurgitation (TR) is associated with increased mortality and is often underdiagnosed due to limitations in imaging modalities. While routine 2-dimensional echocardiography (2DE) demonstrates frequent disagreement with cardiac magnetic resonance imaging (CMR) in classifying TR severity, the incremental value of 3-dimensional echocardiography (3DE) remains unknown also due to the lack of a generalizable grading scheme across imaging modalities. Therefore, this study provides an intermodality comparison of all 3 imaging modalities (2DE, 3DE, and CMR) in evaluating TR severity and proposes an adapted 5-class grading scheme for TR severity using CMR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 144 patients with symptomatic TR were analyzed across 2 cohorts: a derivation cohort (n=91) from the University Hospital of Munich and a validation cohort (n=53) from the Heart Center Leipzig. All patients underwent multimodality imaging, including transthoracic 2DE, transesophageal 3DE, and CMR. The adapted 5-class CMR-based grading scheme was proposed and externally validated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the derivation cohort (median age 81 years, 66% female), TR severity grading by 3DE highly correlated with CMR (87% concordance within a 1-grade difference), significantly outperforming 2DE (68% concordance). While 3DE underestimated RV dimensions compared with CMR (<i>P</i>&lt;0.001), it provided a comparable measure of TR severity and RV function. 2DE achieved the lowest accuracy rates compared with CMR (34.5%; <i>P</i>=0.005) with frequent overestimation of TR severity. An overestimation of TR severity by 3DE compared with CMR was significantly less frequent than with 2DE (21% versus 56%; <i>P</i>&lt;0.001). Cohen κ analysis confirmed a substantial and superior agreement between 3DE and CMR compared with 2DE (κ=0.63 versus 0.41; <i>P</i>=0.01). The results were externally validated, showing comparable results within the derivation and validation cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: 3DE provides an accurate assessment of TR severity comparable to CMR. The proposed 5-class grading scheme for TR severity using CMR demonstrates high accuracy and external validity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116010</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017638>10.1161/CIRCIMAGING.124.017638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116010</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Philipp M Doldi</dc:creator>
<dc:creator>Ludwig T Weckbach</dc:creator>
<dc:creator>Nicola Fink</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Cecilia Ennin</dc:creator>
<dc:creator>Julien Dinkel</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Rebecca Hahn</dc:creator>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>Christian Besler</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>3D Echocardiographic and CMR Imaging for the Assessment of Right Ventricular Function and Tricuspid Regurgitation Severity</dc:title>
<dc:identifier>pmid:40116010</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017638</dc:identifier>
</item>
<item>
<title>Severe Mitral Regurgitation in Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Severe MR in paradoxical low-flow, low-gradient severe aortic stenosis is associated with adverse outcomes and distinctive left ventricular remodeling. Aortic valve replacement improves survival across all MR grades, with greater impact in severe MR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017598. doi: 10.1161/CIRCIMAGING.124.017598. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Severe mitral regurgitation (MR) also causes a low-flow state, adding complexity to diagnosis and management. This study aimed to examine the impact of severe MR on outcomes in paradoxical low-flow, low-gradient severe aortic stenosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from an institutional echo database identified 1189 patients with adjudicated severe aortic stenosis (aortic valve area ≤1.0 cm<sup>2</sup>), low transaortic gradients (mean gradient &lt;40 mm Hg), preserved left ventricular ejection fraction (≥50%), and low-flow rate (Q ≤210 mL/s) to confirm paradoxical low-flow, low-gradient severe aortic stenosis. Subgroups were based on MR severity (severe and nonsevere). Clinical outcomes included all-cause mortality, aortic valve replacement, heart failure hospitalizations, and a composite outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the severe MR group (n=80), patients had lower flow rates, increased left ventricular dimensions, and a more eccentric hypertrophy pattern compared with nonsevere MR (n=1109). Over a follow-up of up to 5 years, severe MR correlated with higher all-cause mortality (<i>P</i>=0.02) and aortic valve replacement rates (<i>P</i>=0.012). After adjustment, severe MR was independently associated with increased all-cause mortality risk (hazard ratio, 1.43; <i>P</i>=0.011) and composite outcome (hazard ratio, 1.64; <i>P</i>&lt;0.001). Aortic valve replacement significantly reduced mortality at every MR degree, with the most substantial impact in severe MR (hazard ratio, 0.18; <i>P</i>&lt;0.001). Propensity-adjusted models demonstrated a stronger aortic valve replacement impact with increasing MR degree (<i>P</i><sub>interaction</sub>=0.044).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Severe MR in paradoxical low-flow, low-gradient severe aortic stenosis is associated with adverse outcomes and distinctive left ventricular remodeling. Aortic valve replacement improves survival across all MR grades, with greater impact in severe MR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116009</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017598>10.1161/CIRCIMAGING.124.017598</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116009</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shani Dahan</dc:creator>
<dc:creator>Jacob Dal-Bianco</dc:creator>
<dc:creator>Ygal Plakht</dc:creator>
<dc:creator>Mayooran Namasivayam</dc:creator>
<dc:creator>Romain Capoulade</dc:creator>
<dc:creator>Xin Zeng</dc:creator>
<dc:creator>Jonathan J Passeri</dc:creator>
<dc:creator>Evin Yucel</dc:creator>
<dc:creator>Michael H Picard</dc:creator>
<dc:creator>Robert A Levine</dc:creator>
<dc:creator>Judy Hung</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>Severe Mitral Regurgitation in Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis</dc:title>
<dc:identifier>pmid:40116009</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017598</dc:identifier>
</item>
<item>
<title>CT Predictors of Epicardial Coronary Spasm in Patients With Angina and Nonobstructive Coronary Arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For patients with nonobstructive coronary arteries, a prespasm provocation test using a noninvasive comprehensive assessment with CCTA may help identify those at high risk for VSA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017565. doi: 10.1161/CIRCIMAGING.124.017565. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Recent studies have shown that vasospastic angina (VSA) is associated with myocardial bridge (MB) and pericoronary adipose tissue inflammation. We aimed to investigate the clinical and coronary computed tomography angiographic (CCTA) features that could predict VSA in patients with angina and nonobstructive coronary arteries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We retrospectively studied patients with nonobstructive coronary arteries who underwent a spasm provocation test and CCTA within 3 months before the spasm provocation test. Pericoronary adipose tissue inflammation was evaluated using the fat attenuation index (FAI) of the proximal reference diameter and the inner 2 mm adipose tissue layer (FAI<sub>2mm</sub>) from the vessel wall. Coronary plaques were qualitatively classified as noncalcified or calcified plaques in each vessel. In addition, MB was evaluated in the left descending artery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 142 patients, with 55 (38.7%) diagnosed with VSA. Factors associated with VSA included male sex (74.5% versus 51.7%, <i>P</i>=0.01), smoking history (70.9% versus 52.9%, <i>P</i>=0.05), CCTA-defined MB (49.1% versus 28.7%, <i>P</i>=0.02), and FAI, especially FAI<sub>2mm</sub> in the right coronary artery-FAI<sub>2mm</sub> (-68.8 Hounsfield unit versus -74.0 Hounsfield unit, <i>P</i>&lt;0.01), as well as the presence of CCTA-defined mixed or noncalcified plaque anywhere in the coronary tree (65.5% versus 39.1%, <i>P</i>&lt;0.01). In a multivariable analysis, CCTA-defined MB (odds ratio, 2.23 [95% CI, 1.03-4.83]; <i>P</i>=0.04), right coronary artery-FAI<sub>2mm</sub> (odds ratio, 1.07 [95% CI, 1.02-1.12]; <i>P</i>&lt;0.01), and the presence of mixed or noncalcified plaque (odds ratio, 3.15 [95% CI, 1.45-6.80]; <i>P</i>&lt;0.01) were independently associated with VSA. A combination of CCTA-defined MB in the left descending artery, high right coronary artery-FAI<sub>2mm</sub> (≥-72.6 Hounsfield unit, median), and CCTA-defined mixed or noncalcified plaque in the coronary tree predicted VSA with a 75.0% probability, while the absence of all 3 factors precluded VSA with 95.6% probability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with nonobstructive coronary arteries, a prespasm provocation test using a noninvasive comprehensive assessment with CCTA may help identify those at high risk for VSA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116006</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017565>10.1161/CIRCIMAGING.124.017565</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116006</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Takashi Mineo</dc:creator>
<dc:creator>Eisuke Usui</dc:creator>
<dc:creator>Yoshihisa Kanaji</dc:creator>
<dc:creator>Masahiro Hada</dc:creator>
<dc:creator>Tatsuhiro Nagamine</dc:creator>
<dc:creator>Hiroki Ueno</dc:creator>
<dc:creator>Kai Nogami</dc:creator>
<dc:creator>Mirei Setoguchi</dc:creator>
<dc:creator>Tomohiro Tahara</dc:creator>
<dc:creator>Tatsuya Sakamoto</dc:creator>
<dc:creator>Masahiro Hoshino</dc:creator>
<dc:creator>Tomoyo Sugiyama</dc:creator>
<dc:creator>Taishi Yonetsu</dc:creator>
<dc:creator>Tetsuo Sasano</dc:creator>
<dc:creator>Tsunekazu Kakuta</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>CT Predictors of Epicardial Coronary Spasm in Patients With Angina and Nonobstructive Coronary Arteries</dc:title>
<dc:identifier>pmid:40116006</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017565</dc:identifier>
</item>
<item>
<title>MRI-Extracellular Volume Fraction Versus Histological Amyloid Load in Cardiac Amyloidosis: The Importance of T2 Mapping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40116000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with ATTRwt-CM and prolonged T2, MRI-ECV did not accurately reflect histological amyloid load. Our findings underscore the need for a multiparametric imaging approach, combining both ECV and T2 mapping, to better characterize myocardial tissue in patients with ATTRwt-CM, and further prospective research in larger and more diverse cohorts is needed to validate our results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar 21:e017427. doi: 10.1161/CIRCIMAGING.124.017427. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: MRI-derived myocardial extracellular volume fraction (ECV) is elevated in the presence of fibrosis, amyloid deposition, inflammation and edema. In patients with cardiac amyloidosis and prolonged T2 due to concomitant inflammation or edema, MRI-ECV may not correctly reflect histological amyloid load. The authors sought to determine whether MRI-ECV can accurately reflect histological amyloid load in 2 groups of patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), with and without T2 prolongation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This retrospective study included consecutive patients with ATTRwt-CM who underwent endomyocardial biopsy and cardiac MRI from March 2017 to October 2021 for initial evaluation of ATTRwt-CM. We measured MRI-ECV and T2, and evaluated correlation between MRI-ECV and amyloid load from endomyocardial biopsy by means of Pearson correlation analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 44 patients (mean age, 75±6 years [SD]; 40 men), 24 showed T2 prolongation (T2≥50 milliseconds). All specimens obtained by endomyocardial biopsy were suitable for analysis. The interval between endomyocardial biopsy and cardiac MRI examination was a median of 3 days (interquartile range, 2-4). In the absence of T2 prolongation due to increased water content, MRI-ECV and amyloid load showed a moderately significant correlation (Spearman ρ=0.50, <i>P</i>=0.03). However, in the presence of T2 prolongation, there was no significant correlation between MRI-ECV and amyloid load (Spearman ρ=-0.05, <i>P</i>=0.83).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with ATTRwt-CM and prolonged T2, MRI-ECV did not accurately reflect histological amyloid load. Our findings underscore the need for a multiparametric imaging approach, combining both ECV and T2 mapping, to better characterize myocardial tissue in patients with ATTRwt-CM, and further prospective research in larger and more diverse cohorts is needed to validate our results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40116000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40116000</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017427>10.1161/CIRCIMAGING.124.017427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40116000</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Masafumi Kidoh</dc:creator>
<dc:creator>Seitaro Oda</dc:creator>
<dc:creator>Seiji Takashio</dc:creator>
<dc:creator>Mami Morioka</dc:creator>
<dc:creator>Naoto Kuyama</dc:creator>
<dc:creator>Tetsuya Oguni</dc:creator>
<dc:creator>Takeshi Nakaura</dc:creator>
<dc:creator>Yasunori Nagayama</dc:creator>
<dc:creator>Yasuhiro Izumiya</dc:creator>
<dc:creator>Kenichi Tsujita</dc:creator>
<dc:creator>Toshinori Hirai</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>MRI-Extracellular Volume Fraction Versus Histological Amyloid Load in Cardiac Amyloidosis: The Importance of T2 Mapping</dc:title>
<dc:identifier>pmid:40116000</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017427</dc:identifier>
</item>
<item>
<title>Physical Activity Reduction in Patients Following ICD Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115999/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Arrhythm Electrophysiol. 2025 Mar 21:e013196. doi: 10.1161/CIRCEP.124.013196. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115999/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40115999</a> | DOI:<a href=https://doi.org/10.1161/CIRCEP.124.013196>10.1161/CIRCEP.124.013196</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115999</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael Christof</dc:creator>
<dc:creator>Alex Page</dc:creator>
<dc:creator>Spencer Rosero</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Arrhythmia and electrophysiology</dc:source>
<dc:title>Physical Activity Reduction in Patients Following ICD Therapy</dc:title>
<dc:identifier>pmid:40115999</dc:identifier>
<dc:identifier>doi:10.1161/CIRCEP.124.013196</dc:identifier>
</item>
<item>
<title>Performance of AlphaMissense and Other In Silico Predictors to Determine Pathogenicity of Missense Variants in Sarcomeric Genes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Genom Precis Med. 2025 Mar 21:e004922. doi: 10.1161/CIRCGEN.124.004922. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40115995</a> | DOI:<a href=https://doi.org/10.1161/CIRCGEN.124.004922>10.1161/CIRCGEN.124.004922</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115995</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mario Ruiz</dc:creator>
<dc:creator>Juan Pablo Ochoa</dc:creator>
<dc:creator>Candela Migoyo-Bettoni</dc:creator>
<dc:creator>Jorge de la Barrera</dc:creator>
<dc:creator>Alba Delrio-Lorenzo</dc:creator>
<dc:creator>Manuel A Fernández-Rojo</dc:creator>
<dc:creator>Ines Martinez-Martin</dc:creator>
<dc:creator>Jorge Alegre-Cebollada</dc:creator>
<dc:creator>Enrique Lara-Pezzi</dc:creator>
<dc:creator>Fatima Sanchez-Cabo</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Genomic and precision medicine</dc:source>
<dc:title>Performance of AlphaMissense and Other In Silico Predictors to Determine Pathogenicity of Missense Variants in Sarcomeric Genes</dc:title>
<dc:identifier>pmid:40115995</dc:identifier>
<dc:identifier>doi:10.1161/CIRCGEN.124.004922</dc:identifier>
</item>
<item>
<title>National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>In 2014, the Organ Procurement and Transplant Network began reappraisal of the United States heart transplant allocation policy. Driven by ongoing discordance between organ supply and demand, high waitlist mortality, and increasing exception requests, the Thoracic Committee radically redesigned the priority scheme and drafted a 6-tiered algorithm, included durable device complications into policy, expanded broader sharing, and increased the number of mandatory listing variables to develop a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Heart Fail. 2025 Mar 21:e011631. doi: 10.1161/CIRCHEARTFAILURE.124.011631. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In 2014, the Organ Procurement and Transplant Network began reappraisal of the United States heart transplant allocation policy. Driven by ongoing discordance between organ supply and demand, high waitlist mortality, and increasing exception requests, the Thoracic Committee radically redesigned the priority scheme and drafted a 6-tiered algorithm, included durable device complications into policy, expanded broader sharing, and increased the number of mandatory listing variables to develop a future heart allocation score. This became the 2018 New Heart Allocation Policy. Changes in allocation priority have resulted in a significant increase in the use of temporary mechanical circulatory support in waitlisted candidates with a concomitant decrease in the number of patients bridged to transplanted with durable left ventricular assist device support. The number of exception requests continues to increase, particularly for patients listed status 2 and for multiorgan transplants. Importantly, fewer patients are being delisted for clinical improvement, suggesting missed opportunities for recovery. The current review will critically evaluate the 2018 heart allocation policy 6 years later, briefly focusing on the history of heart allocation in the United States, the current and evolving algorithms for candidate prioritization including continuous distribution, the impact of technology and innovation on transplant rates and future policy development, and the ongoing regulatory oversight and governance changes in the Organ Procurement and Transplant Network.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40115988</a> | DOI:<a href=https://doi.org/10.1161/CIRCHEARTFAILURE.124.011631>10.1161/CIRCHEARTFAILURE.124.011631</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115988</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lauren K Truby</dc:creator>
<dc:creator>Liviu Klein</dc:creator>
<dc:creator>Jane E Wilcox</dc:creator>
<dc:creator>Maryjane Farr</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Heart failure</dc:source>
<dc:title>National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later</dc:title>
<dc:identifier>pmid:40115988</dc:identifier>
<dc:identifier>doi:10.1161/CIRCHEARTFAILURE.124.011631</dc:identifier>
</item>
<item>
<title>Postimplantation Size of WATCHMAN FLX Pro: A New Left Atrial Appendage Closure System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40115980/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250322141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar 21:e015056. doi: 10.1161/CIRCINTERVENTIONS.124.015056. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40115980/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250322141401&v=2.18.0.post9+e462414">40115980</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.015056>10.1161/CIRCINTERVENTIONS.124.015056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40115980</guid>
<pubDate>Fri, 21 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tetsuma Kawaji</dc:creator>
<dc:creator>Shun Hojo</dc:creator>
<dc:creator>Ryota Takahashi</dc:creator>
<dc:creator>Masashi Kato</dc:creator>
<dc:creator>Takafumi Yokomatsu</dc:creator>
<dc:date>2025-03-21</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Postimplantation Size of WATCHMAN FLX Pro: A New Left Atrial Appendage Closure System</dc:title>
<dc:identifier>pmid:40115980</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.015056</dc:identifier>
</item>





























</channel>
</rss>